Research in context**Evidence before this study**We systematically searched PubMed, Embase, clinical trial registries ([ClinicalTrials.gov](http://ClinicalTrials.gov){#interrefs10}, the International Clinical Trials Registry Platform Search Portal, and the Chinese Clinical Trial Registry), and preprint servers (*bioRxiv* and *medRxiv*) from inception until March 27, 2020 ([appendix pp 126--30](#sec1){ref-type="sec"}) for research articles in English, Chinese, Spanish, and Italian (see [appendix p 126](#sec1){ref-type="sec"} for search terms). No contemporary large-scale evidence was found that investigated the real-world safety of hydroxychloroquine compared with other first-line disease-modifying antirheumatic drugs, especially in combination with macrolide antibiotics such as azithromycin, which have been proposed for use as a treatment for COVID-19. Systematic reviews that have informed European guidelines focused on severe adverse events associated with biological therapies with little high-level evidence focused on hydroxychloroquine. Severe cardiovascular adverse events, mostly lethal arrhythmias and heart failure, have been described in independent retrospective case series and case reports, and reported within the US Food and Drug Administration adverse events database.**Added value of this study**This study uses state-of-the-art methods to control for residual confounding and bias and shows comparable results across 14 international health databases. Hydroxychloroquine does not seem to confer increased risk when used in patients with rheumatoid arthritis without contraindications in the short term (up to 30 days) compared with sulfasalazine, but confers an increased risk of cardiovascular mortality when used long term. Short-term treatment with hydroxychloroquine plus azithromycin appears to be associated with elevated risk of cardiovascular mortality, angina, and heart failure compared with hydroxychloroquine plus amoxicillin.**Implications of all the available evidence**Short-term use of hydroxychloroquine appears to confer no increased risk in patients with rheumatoid arthritis without contraindications, but hydroxychloroquine in combination with azithromycin appears to be associated with serious cardiovascular adverse events and should therefore be used with caution.

Introduction {#cesec10}
============

Hydroxychloroquine, which is most commonly used as the first-line treatment in patients with autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE), has gained extensive media coverage as a potential antiviral agent for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19.[@bib1], [@bib2], [@bib3], [@bib4], [@bib5] Unfortunately, the exponential generation of research into hydroxychloroquine has led to confusion in the rheumatological community regarding the safety implications of hydroxychloroquine within its traditional uses.

Early in the COVID-19 pandemic, publicity focused on a study from France[@bib6] showing faster recovery and reduction in viral load in patients treated with high-dose hydroxychloroquine plus azithromycin, a macrolide antibiotic, compared with patients receiving standard treatment available at the time. This report led to widespread use of high-dose hydroxychloroquine either alone or with azithromycin. Subsequently, serious cardiac adverse events associated with QT segment prolongation that could lead to potentially lethal arrhythmia and cardiovascular-related death were identified in patients taking hydroxychloroquine in several health-care centres in the USA and Brazil.[@bib7], [@bib8], [@bib9], [@bib10] Because of these reports of increased risk, emergency authorisation of hydroxychloroquine by medicines regulators was retracted, statements cautioning against hydroxychloroquine use were released, and randomised trials were stopped.[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15]

European guidelines for the treatment of patients with rheumatoid arthritis contain little high-level evidence for the safety of hydroxychloroquine, and most systematic reviews of rheumatoid arthritis treatments have focused on biological therapies.[@bib16], [@bib17] Before the COVID-19 pandemic, evidence for hydroxychloroquine safety was largely found in retrospective case series and case reports, or within pharmaceutical adverse events registers.[@bib18], [@bib19], [@bib20] Azithromycin and macrolides in general are also known to induce cardiotoxicity and to interact with other drugs that prolong QTc.[@bib21], [@bib22], [@bib23]

The combination of minimal large-scale hydroxychloroquine safety studies before this pandemic, and the extensive research suggesting risks associated with hydroxychloroquine use that has been produced during 2020 is of great concern to both patients and clinicians. We therefore aimed to assess the safety of hydroxychloroquine alone compared with sulfasalazine and of hydroxychloroquine in combination with azithromycin (compared with hydroxychloroquine in combination with amoxicillin), in part to provide clarity for patients taking hydroxychloroquine for rheumatoid arthritis.

Methods {#cesec20}
=======

Study design and participants {#cesec30}
-----------------------------

In this multinational, retrospective study, new user cohort studies were used as recommended by methodological guidelines[@bib24] for observational drug safety research to estimate the safety of hydroxychloroquine alone or in combination with macrolide antibiotics in patients with rheumatoid arthritis. Sulfasalazine and amoxicillin were chosen as active comparators because they have similar indications as the target treatments (hydroxychloroquine and azithromycin, respectively). Participants were included if they had a history of rheumatoid arthritis (a condition occurrence or observation indicating rheumatoid arthritis any time before or on the same day as therapy initiation), were aged 18 years or older at the index event, and had at least 365 days of continuous observation time before the index event.

As a secondary analysis, a self-controlled case series was used to estimate the safety of hydroxychloroquine in the wider population, including patients without rheumatoid arthritis. For this analysis, all prevalent users of hydroxychloroquine were included, regardless of rheumatoid arthritis status or indication.

All data partners received approval or waiver from their institutional review boards in accordance with their institutional governance guidelines. The full study protocol is available online.

Data sources {#cesec40}
------------

Electronic health records (EHRs) and administrative claims data were mapped to the Observational Medical Outcomes Partnership common data model (version 5.0 or higher) and analysed in a distributed network as part of an international effort with the Observational Health Data Science and Informatics community, including 14 databases: IQVIA (Durham, NC, USA) Disease Analyzer Germany (ambulatory electronic medical record \[EMR\] from Germany); Japanese Medical Data Center Claims Database (Tokyo, Japan); Integrated Primary Care Information (IPCI; Rotterdam, Netherlands; primary care EMR); Information System for the Development of Research in Primary Care (SIDIAP; Barcelona, Spain; primary care EMR); Clinical Practice Research Datalink (CPRD; London, UK) and IQVIA UK (London, UK) Integrated Medical Record Data (IMRD; primary care EMRs); and IBM MarketScan (Somers, NY, USA) Commercial Claims and Encounters (CCAE), Optum (Eden Prairie, MN, USA) de-identified Clinformatics Data Mart Database (Clinformatics), Optum EHR (Optum de-identified Electronic Health Record dataset), IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Multi-State Medicaid Database (MDCD), IQVIA Open Claims, US Department of Veterans Affairs (VA; Salt Lake City, UT, USA), and IQVIA US Ambulatory EMR (USA).

Self-controlled case series were done on a subset of these databases as a secondary analysis: CCAE, CPRD, Clinformatics, MDCD, MDCR, and VA. A description of these data sources is available in the [appendix (pp 3--4)](#sec1){ref-type="sec"}.

Study period and outcomes {#cesec50}
-------------------------

The study period started from Sept 1, 2000, and ended at the latest available date for all data sources in 2020. Follow-up for each of the cohorts started at an index date defined by the first dispensing or prescription of the target or comparator drug as described in the cohort definitions ([appendix pp 5--8](#sec1){ref-type="sec"}). Two periods were considered to define time at risk. For a short-term, intention-to-treat analysis, follow-up started 1 day after the index date and continued until the first of: outcome of interest, loss to follow-up, or 30 days after the index date to resemble the duration of COVID-19 treatment regimens.[@bib6] For a longer-term, on-treatment analysis, follow-up started 1 day after the index date and continued until the earliest of: outcome of interest, loss to follow-up, or discontinuation, with an added washout time of 14 days. Continued use of the same treatment was inferred by allowing up to 90-day gaps between dispensing or prescription records. Additional detail on the exposure cohorts is available in the [appendix (pp 5--8)](#sec1){ref-type="sec"}.

For self-controlled case series, periods of persistent exposure to hydroxychloroquine were generated allowing up to 90-day gaps between dispensing or prescription records. Patients were followed up for their entire observation time (eg, from enrolment to disenrolment in each database), and rates of each of the outcomes calculated in periods of exposure and non-exposure time.

The proposed code lists for the identification of the study population and for the study exposures were created by clinicians with experience in the management of rheumatoid arthritis using ATLAS, and reviewed by four clinicians and one epidemiologist.[@bib25]

16 severe adverse events were analysed. Hospital-based events, which are not available in primary care records (CPRD, IMRD, and SIDIAP), included gastrointestinal bleeding, acute renal failure, acute pancreatitis, myocardial infarction, stroke, transient ischaemic attack, and cardiovascular events (composite). Additionally, angina or chest pain, heart failure, cardiac arrhythmia, bradycardia, venous thromboembolism, end-stage renal disease, and hepatic failure were analysed from both primary and secondary care data. All-cause mortality outcomes were obtained only from data sources with reliable information on death date (CPRD, IMRD, IPCI, Clinformatics, SIDIAP, and VA) and cardiovascular mortality outcomes from sources with information on cardiovascular events preceding death (CPRD, IMRD, Clinformatics, and VA). All codes for the identification of the 16 proposed study outcomes were based on a previously published paper[@bib26] and are detailed in the [appendix (pp 8--9)](#sec1){ref-type="sec"}. Face validity for each of the outcome cohorts was further reviewed and compared with previous clinical knowledge and existing literature.

A list of negative control outcomes was also assessed for which there is no known causal relationship with any of the drugs of interest. These outcomes were identified using a semi-automatic process based on data extracted from the literature, product labels, and spontaneous reports, and confirmed by manual review by three clinicians (JCEL, AP-U, and DP-A).[@bib27] A full list of the codes that were used to identify negative control outcomes and details on covariate and confounder identification are provided in the [appendix (pp 10--11)](#sec1){ref-type="sec"}.

Statistical analysis {#cesec60}
--------------------

We used propensity score stratification (into quintiles) to adjust for observed confounders, using a large-scale regularised logistic regression fitted with a LASSO penalty and with the optimal hyperparameter determined through ten-fold cross-validation.[@bib28] Baseline patient characteristics were constructed for inclusion as potentially confounding covariates.[@bib29] Predictor variables included were based on all observed patient characteristics as available in each data source, including conditions, procedures, visits, observations, and measurements. We plotted the propensity score distribution and assessed covariate balance expressed as the standardised difference of the mean for every covariate before and after propensity score stratification. A standardised difference of more than 0·1 indicated a non-negligible imbalance between exposure cohorts.[@bib30] Cox proportional hazards models conditioned on the propensity score strata were fitted to estimate hazard ratios (HRs) according to treatment status. Negative control outcomes analyses and empirical calibration were used to minimise potential unresolved confounding, with calibrated HRs and 95% CIs estimated.[@bib31], [@bib32]

For self-controlled case series, safety of hydroxychloroquine therapy was assessed separately as a secondary analysis, regardless of indication, comparing exposed and unexposed time periods within the same individuals. The method is self-controlled in that it makes within-person comparisons of event rates during periods of hypothesised increased risk with other periods of baseline risk, which eliminates all time-invariant confounding. Because we do not compare between individuals, the self-controlled case series is robust to between-person differences, even including unmeasured differences (such as genetics). However, the method is vulnerable to time-varying confounders. To adjust for this confounding, we included many time-varying covariates in the models, including age, season, and other drug exposures. A conditional Poisson regression was used to fit the outcome model using the Cyclops package (version 2.0), with a hyperparameter selected through ten-fold cross-validation.[@bib33]

Study diagnostics (power, propensity score distribution, covariate balance, and empirical null distribution) were evaluated by clinicians and epidemiologists to determine which database target comparator outcome analysis variants could produce unbiased estimates ([appendix pp 104--18](#sec1){ref-type="sec"}). Analyses with zero event outcomes or with confounder imbalances with standardised mean difference of more than 0·1 after stratification were excluded from analysis. All analyses were conducted for each database separately, with estimates combined in random-effects meta-analysis methods where the *I* ^2^ value was less than 0·4.[@bib34] The standard errors of the database-specific estimates were adjusted to incorporate estimate variation across databases, where the across-database variance was estimated by comparing each database-specific result to that of an inverse-variance, fixed-effects meta-analysis. No meta-analysis was done where *I* ^2^ for a given drug--outcome pair was 0·4 or more. Of note, when running analysis in a distributed network, it was not possible to link across datasets, and to know the extent of overlap between data.

Small cell counts (n) of less than five (and resulting estimates) are reported as \<n to minimise risk of re-identification. For the cohort analysis, the [CohortMethod package](https://ohdsi.github.io/CohortMethod/){#interrefs20} (version 3.1.0) was used as well as the [Cyclops package](https://ohdsi.github.io/Cyclops){#interrefs30} (version 2.0) for propensity score estimation.[@bib33] All self-controlled case series were run using the [self-controlled case series](https://ohdsi.github.io/SelfControlledCaseSeries/){#interrefs40} package.[@bib35] The full [source code](https://github.com/ohdsi-studies/Covid19EstimationHydroxychloroquine){#interrefs50} for analyses is available online.

This study is registered with the EU Post-Authorisation Studies Register, EUPAS34497.[@bib36]

Role of the funding source {#cesec70}
--------------------------

The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the manuscript, or the decision to submit for publication. All authors had full access to aggregated data in the study, and the lead and senior authors (JCEL, JW, PRy, and DP-A) had final responsibility for the decision to submit for publication.

Results {#cesec80}
=======

956 374 hydroxychloroquine and 310 350 sulfasalazine users were identified, and 323 122 and 351 956 contributed to the analyses of combination therapy of hydroxychloroquine plus azithromycin compared with hydroxychloroquine plus amoxicillin, respectively. Participant counts in each data source are provided in the [appendix (pp 13--65)](#sec1){ref-type="sec"}. Duration of hydroxychloroquine therapy in the long-term analysis varied between databases, and ranged from a median of 43 days (IQR 43--193) in IQVIA US Ambulatory EMR to 338 days (106--1507) in CPRD. [Full details](http://evidence.ohdsi.org:3838/Covid19EstimationHydroxychloroquine/){#interrefs60} can be found in the power tab for each database online.

Compared with sulfasalazine, users of hydroxychloroquine were more likely to be female (eg, 82·0% *vs* 74·3% in CCAE) and less likely to have certain comorbidities such as Crohn\'s disease (0·6% *vs* 1·8% in CCAE) or psoriasis (3·0% *vs* 8·9% in CCAE; [appendix pp 15--16](#sec1){ref-type="sec"}). In CCAE, the mean baseline dose for hydroxychloroquine was 420 mg (SD 463), and 2·8% of patients had an estimated dose of more than 500 mg. All differences were minimised after propensity score stratification, with all reported analyses balanced on all identified confounders. For example, systemic corticosteroid use or a diagnosis of SLE in the year before hydroxychloroquine or sulfasalazine use before propensity score matching was imbalanced but was balanced through propensity score stratification. Full details of all of the variables used within the propensity score are available in the shiny application (population characteristics tab, searching for the variable within the raw setting). Similarly, users of combination hydroxychloroquine plus azithromycin differed from those of hydroxychloroquine plus amoxicillin, with a higher prevalence of acute respiratory disease among azithromycin users (eg, 62·5% *vs* 50·7% in CCAE; [appendix p 43](#sec1){ref-type="sec"}). Again, propensity score methods mitigated these differences, and comparison groups became balanced for all observed confounders after stratification. Detailed baseline characteristics for the two pairs of treatment groups after propensity score stratification in CCAE are detailed in [table 1](#tbl1){ref-type="table"} for illustrative purposes, and a complete list of features for each database comparing before and after propensity score stratification are provided in the [appendix (pp 13--65)](#sec1){ref-type="sec"}. Propensity score distribution plots and negative control outcome analyses can be found in the [appendix (pp 104--118)](#sec1){ref-type="sec"} in addition to all elements of the propensity model and Kaplan-Meier analyses.Table 1Baseline characteristics of users of HCQ versus SSZ, and HCQ plus AZM versus HCQ plus AMX after propensity score stratification in the CCAE database**HCQ *vs* SSZHCQ plus AZM *vs* HCQ plus AMX**HCQ (n=66 604)SSZ (n=22 370)Standardised mean differenceHCQ plus AZM (n=32 586)HCQ plus AMX (n=32 496)Standard mean difference**Age, years**15--190·6%0·6%0·000·5%0·5%\<0·0020--241·8%2·0%−0·011·4%1·4%\<0·0025--292·5%2·7%−0·012·2%2·2%\<0·0030--344·5%4·4%\<0·004·0%3·9%0·0135--397·1%7·1%0·006·8%6·7%\<0·0040--449·7%9·5%0·019·3%9·3%\<0·0045--4913·6%13·4%\<0·0013·2%13·3%\<0·0050--5418·2%18·1%0·0118·1%18·0%\<0·0055--5920·8%20·8%\<0·0021·5%21·8%−0·0160--6419·4%19·8%−0·0121·1%21·1%\<0·0065--691·8%1·6%0·012·0%2·0%\<0·00**Sex**Female80·1%79·7%0·0186·3%86·2%0·00Male19·9%20·3%0·0113·7%13·8%0·00**Medical history: general**Chronic obstructive lung disease4·3%4·5%−0·015·0%5·2%−0·01Depressive disorder13·3%13·5%\<0·0014·7%14·8%\<0·00Diabetes13·6%13·8%−0·0113·2%13·1%\<0·00Hyperlipidaemia31·2%31·4%\<0·0030·4%30·3%\<0·00Pneumonia4·0%4·0%\<0·005·7%5·5%0·01Renal impairment3·0%2·8%0·014·2%4·1%\<0·00Urinary tract infections11·6%11·5%\<0·0014·0%13·9%\<0·00**Medical history: cardiovascular disease**Atrial fibrillation1·4%1·3%0·011·7%1·8%\<0·00Cerebrovascular disease2·8%2·9%−0·013·1%3·2%−0·01Coronary arteriosclerosis4·4%4·6%−0·015·0%4·9%\<0·00Heart disease15·5%15·4%\<0·0017·8%17·9%\<0·00Heart failure1·9%2·0%\<0·002·5%2·4%0·01Ischaemic heart disease3·0%3·1%−0·013·3%3·1%0·01**Medication use**Agents acting on the renin--angiotensin system24·5%24·6%\<0·0027·1%26·9%\<0·00Antidepressants36·3%36·5%\<0·0043·0%42·8%\<0·00Drugs for obstructive airway diseases29·5%29·5%\<0·0041·1%40·7%0·01Immunosuppressants43·4%43·6%\<0·0051·1%51·2%\<0·00Opioids39·0%39·3%−0·0141·4%41·2%\<0·00Psycholeptics33·4%33·3%\<0·0038·2%38·1%\<0·00[^2]

Database-specific and subtotal (meta-analysis) counts and rates of key outcomes (cardiovascular mortality, all-cause mortality, chest pain or angina, and heart failure) observed in the prespecified 30-day intention-to-treat analysis are shown in [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"} . Mortality risk was assessed only using databases with reliable death capture: Clinformatics, CPRD, IMRD, IPCI, SIDIAP, and VA. For the analysis of hydroxychloroquine versus sulfasalazine, four databases (Clinformatics, CPRD, IMRD, and VA) were used to analyse all-cause mortality (no events were seen in SIDIAP and IPCI), and three databases (Clinformatics, CPRD, and VA) were used to analyse cardiovascular mortality. Two databases were used to analyse all-cause mortality and cardiovascular mortality for hydroxychloroquine plus azithromycin versus hydroxychloroquine plus amoxicillin (Clinformatics and VA); no events were seen in the other datasets. Mortality rates ranged from 4·81 per 1000 person-years in hydroxychloroquine users in Clinformatics to 17·13 per 1000 person-years among hydroxychloroquine users in VA, with cardiovascular-specific mortality ranging from 3·43 per 1000 person-years in hydroxychloroquine users in VA to less than 4·25 per 1000 person-years in sulfasalazine users in the same data source. Database-specific counts and incidence rates for severe adverse events stratified by drug use are detailed in full in the [appendix (pp 66--71)](#sec1){ref-type="sec"}.Table 2Patient counts, event counts, and incidence rates of key outcomes according to HCQ versus SSZ use**30-day follow-upOn-treatment follow-up**HCQ usersSSZ usersHCQ eventsSSZ eventsHCQ incidence rate (per 1000 person-years)SSZ incidence rate (per 1000 person-years)HCQ usersSSZ usersHCQ eventsSSZ eventsHCQ incidence rate (per 1000 person-years)SSZ incidence rate (per 1000 person-years)**Cardiovascular-related mortality**Clinformatics51 28017 38916\<53·85\<3·5451 28017 389234254·392·00CPRDNANANANANANA912711 3987250·390·94VA32 02814 3499\<53·43\<4·2532 02814 349315655·693·71Meta-analysis83 30831 73825\<103·68\<3·8692 43543 1365561154·392·03**All-cause mortality**Clinformatics51 28017 38920104·817·0951 28017 389527669·885·29CPRD912711 398658·035·35912711 39825338614·0214·56IMRD88518460\<56\<6·918·668851846021424112·3212·72VA32 02814 349451717·1314·4532 02814 349135632724·5118·65Meta-analysis101 28651 596\<7638\<9·209·02NANANANANANA**Chest pain or angina**AmbEMR57 14015 2681223126·0424·7657 14015 26845111224·4419·89CCAE65 93522 17344014382·4179·6265 93522 173335481055·0058·80Clinformatics50 69817 22139616696·62119·3450 69817 221318582966·1372·48CPRD911411 388101713·4018·22911411 38826042214·9916·78DAGermany38845045\<55\<15·6912·0738845045313612·3610·26IMRD8843845291012·4514·468843845223529314·0016·25MDCD798221778023123·50130·437982217746710087·3485·81MDCR15 690515012949101·25117·4315 6905150117827971·3875·12OpenClaims617 628182 776267480452·8353·68617 628182 77631 161619838·5938·11OptumEHR76 84421 549629143101·4682·23NANANANANANAVA31 82414 2761305449·8946·2031 82414 276182261135·8837·31Meta-analysis945 582305 475\<46241445\<59·8657·90868 738283 92642 144969040·3637·07**Heart failure**AmbEMR57 38315 30542108·927·9657 38315 305182539·769·37CCAE66 60422 3703055·552·7566 60422 370305744·645·07Clinformatics51 20417 356842520·2317·7651 20417 35691520717·5516·90CPRD912611 397\<5\<5\<6·69\<5·35912611 39716360·891·36DAGermany38855042\<5\<5\<15·68\<12·083885504211224·296·22IMRD88528460\<5\<5\<6·91\<7·228852846015210·861·11MDCD8072219515\<522·81\<27·99807221951182820·5523·02MDCR15 8085171391930·3045·2215 808517158614133·1336·29OpenClaims620 244183 35074921414·7114·22620 244183 35012 246224614·3613·22OptumEHR77 81321 7682375037·6428·39NANANANANANAVA31 89514 307561721·4214·4931 89514 30789729616·7517·42Meta-analysis950 886306 721\<1267\<360\<16·28\<14·34873 073284 95315 291312413·8511·43[^3]Table 3Patient counts, event counts, and incidence rates of key outcomes according to HCQ plus AZM versus HCQ plus AMX use**30-day follow-upOn-treatment follow-up**HCQ plus AZM usersHCQ plus AMX usersHCQ plus AZM eventsHCQ plus AMX eventsHCQ plus AZM incidence rate (per 1000 person-years)HCQ plus AMX incidence rate (per 1000 person-years)HCQ plus AZM usersHCQ plus AMX usersHCQ plus AZM eventsHCQ plus AMX eventsHCQ plus AZM incidence rate (per 1000 person-years)HCQ plus AMX incidence rate (per 1000 person-years)**Cardiovascular-related mortality**Clinformatics23 59724 521964·703·0223 59724 52196825·565·58VA62348005461890·6027·496234800515711514·6010·20Meta-analysis29 83132 526552422·709·0829 83132 5262531979·037·59**All-cause mortality**Clinformatics23 59724 52117178·888·5523 59724 52126827615·5618·85VA623480059152179·2379·426234800555051851·1645·97Meta-analysis29 83132 5261086944·5826·1229 83132 52681879429·2430·64CCAE32 61032 50713114·924·1732 61032 507117944·334·33Clinformatics23 56524 484302915·7014·6223 56524 48417914710·6010·19MDCD38033808\<56\<16·2119·4038033808292711·4613·46MDCR8119925416924·3311·968119925416614020·4117·34Open Claims216 028232 93818217310·269·05216 028232 938206517328·117·94OptumEHR18 47716 424262017·3515·01NANANANANANAVA62037978331965·5329·156203797815412714·7911·59Meta-analysis308 805327 393\<305267\<12·089·97290 328310 969271022678·488·24**Chest pain or angina**AmbEMR13 09312 028322129·8021·2913 09312 02814211925·6925·31CCAE32 16532 22924121192·7680·9832 16532 2291402114560·4660·54Clinformatics23 20624 254244203130·28103·7023 20624 254101988770·3370·28MDCD37123764303799·97121·563712376412911360·0563·39MDCR799191958185125·60114·207991919551749874·8371·25OpenClaims214 494231 851105088859·7646·74214 494231 8518348722336·2436·37OptumEHR18 03916 191218134150·01102·42NANANANANANAVA612179125850116·9677·526121791234037138·4839·87Meta-analysis318 821337 4241954162975·1359·12300 782321 23311 89710 35640·8240·95**Heart failure**AmbEMR13 15212 053161614·8316·1813 15212 053614910·449·96CCAE32 58632 496302311·368·7332 58632 4961771266·585·82Clinformatics23 54124 468654934·0824·7323 54124 46833731720·3322·63MDCD3796379516952·0829·2137963795654826·2624·83MDCR80859239453368·8843·978085923932229541·6138·34OpenClaims215 732232 72547237026·6819·38215 732232 7254352371417·5017·43OptumEHR18 05416 298996067·7745·45NANANANANANAVA616479597931158·5347·736164795928022928·1721·64Meta-analysis321 110339 03382259131·3221·32303 056322 7355594477817·5817·44[^4]

Least common outcomes among hydroxychloroquine users included bradycardia (eg, incidence rate 0·92 per 1000 person-years in CCAE) and end-stage renal disease (eg, less than 0·92 per 1000 person-years in CCAE), whereas most common outcomes were chest pain or angina (eg, 82·41 per 1000 person-years in CCAE; [table 2](#tbl2){ref-type="table"}) and composite cardiovascular events (eg, 17·96 per 1000 person-years in CCAE).

Database and outcome-specific HRs (uncalibrated and calibrated) are reported in full in the form of forest plots in the [appendix (pp 72--103)](#sec1){ref-type="sec"}. None of the severe adverse events appeared to be consistently increased with the short-term use of hydroxychloroquine (*vs* sulfasalazine) in the 30-day intention-to-treat analyses ([figure 1](#fig1){ref-type="fig"} ), with meta-analytic calibrated HRs ranging from 0·67 (95% CI 0·45--1·01) for hepatic failure to 1·17 (0·90--1·53) for transient ischaemic attack, and 1·36 (0·51--3·63) for cardiovascular mortality ([figure 2](#fig2){ref-type="fig"} ). In our published study protocol, we decided a priori that meta-analytic estimates would only be reported if the *I* ^2^ value was less than 0·4, indicating that there was low heterogeneity between the results included, and that it was appropriate for them to be pooled to produce this final result.[@bib36] For all-cause mortality in the on-treatment analysis, the *I* ^2^ value was 0·71, indicating substantial heterogeneity between results and therefore a summary estimate was not reported. The same is true for gastrointestinal bleeding (*I* ^2^=0·57) and stroke (*I* ^2^=0·58) in the on-treatment analysis.Figure 1Meta-analytic estimates for HCQ versus SSZ and HCQ plus AZM versus HCQ plus AMX new users during 30-day (intention-to-treat) and long-term (on-treatment) follow-upAMX=amoxicillin. AZM=azithromycin. HCQ=hydroxychloroquine. HR=hazard ratio. SSZ=sulfasalazine.Figure 2Source-specific and meta-analytic-specific severe adverse event risk estimates for HCQ versus SSZ and HCQ plus AZM versus HCQ plus AMX new users during 30-day (intention-to-treat) follow-upAmbEMR=IQVIA Ambulatory EMR. AMX=amoxicillin. AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease Analyzer Germany. EMR=electronic medical record. HCQ=hydroxychloroquine. HR=hazard ratio. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM Medicare Supplemental Database. OptumEHR=Optum de-identified Electronic Health Record. SSZ=sulfasalazine. VA=US Department of Veterans Affairs.

Similar findings were seen with the long-term (on-treatment) use of hydroxychloroquine versus sulfasalazine ([figure 1](#fig1){ref-type="fig"}; [figure 3](#fig3){ref-type="fig"} ), with the exception of cardiovascular mortality, which appeared to be inconsistent in the available databases but increased overall in the hydroxychloroquine group when meta-analysed (pooled calibrated HR 1·65 \[95% CI 1·12--2·44\]).Figure 3Source-specific and meta-analytic specific severe adverse event risk estimates for HCQ versus SSZ and HCQ plus AZM versus HCQ plus AMX new users during long-term (on-treatment) follow-upAmbEMR=IQVIA Ambulatory EMR. AMX=amoxicillin. AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease Analyzer Germany. EMR=electronic medical record. HCQ=hydroxychloroquine. HR=hazard ratio. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM Medicare Supplemental Database. OptumEHR=Optum de-identified Electronic Health Record. SSZ=sulfasalazine. VA=US Department of Veterans Affairs.

Self-controlled case series analyses supported the findings of the main analysis, while looking at the effect of hydroxychloroquine use (on treatment *vs* off treatment) regardless of indication, and therefore including patients without rheumatoid arthritis ([table 4](#tbl4){ref-type="table"} ; full results are given in the [appendix pp 119--25](#sec1){ref-type="sec"}).Table 4Summary of self-controlled case series results for HCQ**CCAEClinformaticsCPRDJMDC Claims DatabaseMDCDMDCRVA**Calibrated incidence rate ratioCalibrated 95% CICalibrated incidence rate ratioCalibrated 95% CICalibrated incidence rate ratioCalibrated 95% CICalibrated incidence rate ratioCalibrated 95% CICalibrated incidence rate ratioCalibrated 95% CICalibrated incidence rate ratioCalibrated 95% CICalibrated incidence rate ratioCalibrated 95% CI**Myocardial infarction**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·910·69--1·211·110·81--1·54NANANANANANA1·090·86--1·390·990·73--1·34Primary analysis0·920·70--1·221·020·74--1·40NANANANA0·890·70--1·150·990·78--1·261·000·74--1·36**Acute pancreatitis events**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}NANA1·050·75--1·46NANA2·180·11--43·821·130·86--1·471·030·77--1·360·970·71--1·34Primary analysis0·900·68--1·201·050·75--1·46NANA2·110·14--31·501·120·86--1·460·990·74--1·320·980·71--1·35**Acute renal failure**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·880·67--1·160·960·58--1·59NANA1·330·31--5·71NANA1·080·85--1·37NANAPrimary analysis0·900·69--1·190·990·72--1·37NANA1·390·32--6·1210·80--1·250·970·76--1·231·110·83--1·50**Gastrointestinal bleeding**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}NANA1·130·82--1·55NANA0·250·03--2·440·950·75--1·201·020·81--1·30NANAPrimary analysis1·010·76--1·321·060·77--1·46NANA0·240·03--2·380·950·76--1·200·960·76--1·220·970·72--1·32**Cardiac arrhythmia**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·950·72--1·251·030·74--1·420·950·61--1·470·620·18--2·150·930·74--1·170·850·67--1·090·860·64--1·17Primary analysis0·950·72--1·261·030·74--1·430·950·61--1·480·580·17--1·980·930·74--1·170·860·67--1·100·850·63--1·15**Bradycardia**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}NANA0·910·65--1·270·650·20--2·163·670·26--50·91NANA0·870·68--1·120·880·65--1·20Primary analysis0·720·54--0·960·920·67--1·280·680·21--2·183·690·26--51·540·740·55--0·990·870·68--1·120·930·68--1·26**Chest pain or angina**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·910·69--1·211·070·77--1·480·980·63--1·520·920·45--1·851·070·84--1·380·950·75--1·21NANAPrimary analysis0·910·69--1·211·060·76--1·470·980·63--1·520·910·45--1·841·070·84--1·360·940·74--1·200·980·73--1·33**End-stage renal disease**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}1·020·69--1·51NANA0·910·15--5·49NANANANA0·880·66--1·181·040·76--1·44Primary analysis1·030·76--1·391·260·90--1·760·910·15--5·31NANA1·240·93--1·640·880·66--1·191·020·74--1·40**Heart failure**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·990·75--1·291·150·83--1·581·200·69--2·091·020·50--2·100·950·75--1·201·120·88--1·421·030·76--1·39Primary analysis0·990·75--1·301·130·82--1·561·210·69--2·111·020·49--2·080·950·75--1·201·090·86--1·391·040·77--1·40**Hepatic failure**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·680·50--0·92NANANANA1·540·08--30·150·830·60--1·160·820·58--1·17NANAPrimary analysis0·640·47--0·880·730·52--1·020·090·01--1·351·480·07--33·230·770·55--1·070·810·57--1·150·790·56--1·11**Stroke**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}NANA0·970·70--1·34NANA1·130·36--3·550·900·71--1·141·010·80--1·290·960·71--1·31Primary analysis0·800·61--1·060·900·65--1·24NANA1·140·36--3·590·850·67--1·080·930·73--1·180·980·72--1·34**Cardiovascular events**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}NANA0·900·37--2·21NANA0·510·21--1·250·910·73--1·151·100·87--1·40NANAPrimary analysis0·860·66--1·140·950·69--1·31NANA0·500·20--1·250·860·68--1·081·020·80--1·291·080·80--1·46**Transient ischaemic attack**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·910·69--1·200·940·68--1·30NANANANA0·940·72--1·2310·79--1·28NANAPrimary analysis0·920·70--1·210·930·68--1·29NANANANA0·920·71--1·200·970·76--1·241·200·88--1·65**Venous thromboembolism**Adjusted analysis[\*](#tbl4fn1){ref-type="table-fn"}0·790·54--1·150·860·62--1·180·700·45--1·091·510·62--3·670·880·71--1·100·760·60--0·96NANAPrimary analysis0·810·62--1·070·840·61--1·160·690·44--1·071·510·62--3·670·870·70--1·090·710·56--0·910·860·64--1·16[^5][^6]

All of the obtained database-specific and outcome-specific calibrated HRs for the association between short-term (on-treatment) use of hydroxychloroquine plus azithromycin versus hydroxychloroquine plus amoxicillin are depicted as forest plots in the [appendix (pp 72--103)](#sec1){ref-type="sec"}. Three severe adverse events appeared to be increased with the short-term (30-day intention to treat) use of hydroxychloroquine plus azithromycin compared with hydroxychloroquine plus amoxicillin: chest pain or angina (meta-analytic calibrated HR 1·15 \[95% CI 1·05--1·26\]), heart failure (1·22 \[1·02--1·45\]), and cardiovascular mortality (2·19 \[1·22--3·95\]; [figure 2](#fig2){ref-type="fig"}).

Full results from each dataset, including power, attrition, and population characteristics are available [online](https://data.ohdsi.org/Covid19EstimationHydroxychloroquine/){#interrefs70}. This site also contains all of the cohort diagnostic tools that were examined before unblinding results and before a dataset was included in the meta-analyses. Each dataset was examined for the risk of observed confounding (within the propensity score model, propensity score distribution, and covariate balance with identified variables) or by unobserved confounding (assessing negative control variables within analysis of the risk of systematic error) before their inclusion. These diagnostic tools can be reviewed for each database for each outcome within the shiny application of R (version 3.61) in order to give full transparency of analysis.

Discussion {#cesec90}
==========

To our knowledge, this study is the largest ever analysis of the safety of hydroxychloroquine and hydroxychloroquine plus azithromycin worldwide, examining more than 950 000 hydroxychloroquine and more than 300 000 hydroxychloroquine plus azithromycin users, respectively. Short-term (up to 30 days) hydroxychloroquine treatment among patients with rheumatoid arthritis showed no excess risk of any of the considered severe adverse events compared with sulfasalazine. Short-term treatment is also proposed for COVID-19 therapy and might be informed by the experience of treatment in patients with rheumatoid arthritis. By comparison, long-term hydroxychloroquine therapy appears to be associated with a relative risk increase in cardiovascular-related mortality compared with a roughly equivalent rheumatoid arthritis therapy (sulfasalazine; calibrated HR 1·65 \[95% CI 1·12--2·44\]). Perhaps more worryingly, compared with hydroxychloroquine plus amoxicillin, significant risks were identified for the combination of hydroxychloroquine plus azithromycin even in the short term: increased risk of angina or chest pain (calibrated HR 1·15 \[95% CI 1·05--1·26\]) and heart failure (1·22 \[1·02--1·45\]), and a doubled risk of cardiovascular mortality in the first month of treatment (2·19 \[1·22--3·94\]).

A systematic review of reports on the toxicity of hydroxychloroquine has identified cardiac side-effects, including conduction disorders, heart failure, and ventricular hypertrophy resulting in 12·9% irreversible damage and 30% mortality.[@bib19], [@bib20] Furthermore, interrogation of the US Food and Drug Administration Adverse Event Reporting System database identified 357 adverse events reported for chloroquine.[@bib18] 20% of the events reported were cardiac and included arrhythmia, sudden cardiac death, or heart failure.

Our results suggest that long-term use of hydroxychloroquine leads to increased cardiovascular mortality, which might relate to cumulative effects of hydroxychloroquine leading to an increased risk of QT lengthening and potentially to sudden undetected torsade-de-pointes and cardiovascular death. Although long-term treatment with hydroxychloroquine is not expected for the management of COVID-19, some research suggests that the higher doses prescribed for COVID-19 than for rheumatoid arthritis can, even in the short term, lead to equivalent side-effects given the long half-life of hydroxychloroquine.[@bib19]

In addition, QT lengthening is a known side-effect of all macrolides, including azithromycin, and physicians already use caution when prescribing macrolides concurrently with other medications that can interact to increase the QT interval.[@bib22], [@bib23] In this study, a relative risk of 2·19 (95% CI 1·22--3·94) for cardiovascular death was seen even with short-term hydroxychloroquine plus azithromycin combination therapy, probably arising through their synergistic effects on QT length and subsequent induction of lethal arrhythmia. Considering that hydroxychloroquine and azithromycin are both contraindicated for use in patients with cardiac arrhythmias, this study assumes that clinicians are prescribing these medications for patients as per existing labelling advice. It is therefore concerning that cardiovascular effects were still seen in our study populations, possibly indicating that the true risks of these drugs are understated in the analysis.

It is important to identify potential sources of bias that could limit the study. The analyses are predicated on observing the presence of exposure, outcomes, and covariates in the data, or inferring their absence based on an assumption of complete data capture during a defined observation period during which a person is not expected to be lost to follow-up. In this regard, although there were no missing data that required imputation, each binary variable is subject to potential misclassification error, and the sensitivity and specificity of these variables in each database are unknown. Because of the nature of sudden cardiac death, capturing the true cause of cardiovascular-related mortality is difficult. Although we examined various aspects of cardiac complications as captured by diagnosis codes, the accuracy of evaluations of QT prolongation, ventricular tachycardia, or other arrhythmias would probably be improved with precise electrocardiogram measurements. Exposure misclassification can occur as a result of non-adherence or non-compliance with either treatment and thus could bias the results in either direction, and outcome misclassification might exist because of incomplete or incorrect recording of severe adverse events. Baseline covariates might also be subject to measurement error and, although observing balance on all baseline characteristics after propensity score adjustment provides reassurance that the risk of confounding has been reduced, there remains potential for confounding in any given source for differential misclassification. The consistency of findings across heterogeneous patient populations with disparate data capture processes mitigates this concern. Within the study design, use of routine health-care data in populations across four continents, and including all adults with rheumatoid arthritis was used to minimise selection bias. The self-controlled case series analysis was also added to investigate all users of hydroxychloroquine as an external validation of the hydroxychloroquine findings in the rheumatoid arthritis population via the new user design. To investigate systematic error, study diagnostics were evaluated before unblinding results through interrogation of negative controls.

We have taken into consideration that patients with rheumatoid arthritis taking hydroxychloroquine might also have further autoimmune conditions such as SLE and therefore generate the potential for confounding by indication. We also investigated the incidence of hyperlipidaemia, diabetes, venous thromboembolic disease, and coronary arteriosclerosis before unblinding because of the established evidence that hydroxychloroquine improves survival in patients with SLE through antilipidaemic and antithrombotic mechanisms of action and reduces the development of diabetes in patients with SLE and those with rheumatoid arthritis.[@bib28], [@bib37], [@bib38], [@bib39] We ensured that, when investigating covariate balance after propensity score stratification and matching and before unblinding study results, we did not see unbalanced proportions of patients with a diagnosis of SLE between the groups. Negative control outcome analyses to assess for systematic error also did not identify any residual unobserved confounding in the propensity score analysis, adjusting for thousands of variables within the large-scale propensity score model. Although we have balanced for the coexistence of other conditions and medications through propensity scores, and we tested for residual unobserved confounding to ensure groups were balanced, no direct measure of severity of rheumatoid arthritis was drawn for patients at baseline. The cohort was made from patients who were new users of both hydroxychloroquine and sulfasalazine with a diagnosis of rheumatoid arthritis and without medication use in the previous 365 days, but the potential for differences in baseline rheumatoid arthritis severity not recorded in routinely collected data is also a limitation of the study.

Another criticism is the choice of sulfasalazine as an active comparator. Both hydroxychloroquine and sulfasalazine are second-line conventional synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis, used in addition to, or instead of methotrexate. Although they are not fully equivalent to each other, and no drug can be an exact match, they are each the closest comparator treatment to the other. Appreciating they are not truly equivalent, we took care to ensure that propensity score stratification and negative control analysis for any systematic error ensured that the two groups were as balanced as possible to minimise confounding.

Another potential limitation in this study is the potential for patients to be included in more than one dataset in the USA. Although we ran meta-analyses, which assume populations are independent, we highlight that we are likely to have underestimated variance in our meta-analytic estimates. We also acknowledge the limitation that although 14 databases were used in total, mortality analysis was restricted to databases with good coverage of this outcome (ie CPRD, IMRD, IPCI, VA, and Clinformatics). Similarly, as we do not know the baseline risk of serious adverse events within this population, we cannot report absolute risk of these events in patients with rheumatoid arthritis, and this limitation must be acknowledged.

In this large-scale, international, real-world data network study, hydroxychloroquine appears to be largely safe for short-term use in patients with rheumatoid arthritis compared with sulfasalazine, but when used in combination with azithromycin, this therapy carries a relative risk of 2·19 for cardiovascular death compared with hydroxychloroquine combined with amoxicillin. The collective experience of almost a million patients builds our confidence in the evidence around the safety profile of hydroxychloroquine. In line with consensus expert guidance, our findings suggest that a cautious assessment of cardiovascular risk is needed before initiating high-dose hydroxychloroquine or hydroxychloroquine plus azithromycin combination therapy, and in long-term monitoring of patients with rheumatoid arthritis, especially those with cardiovascular risk factors.[@bib8]

Data sharing {#cesec100}
============

Open science is a guiding principle within Observational Health Data Sciences and Informatics. As such, we provide unfettered access to all open-source analysis tools used in this study via <https://github.com/OHDSI/>, as well as all data and results artefacts that do not include patient-level health information via <http://evidence.ohdsi.org/Covid19EstimationHydroxychloroquine>. Data partners contributing to this study remain custodians of their individual patient-level health information and hold either exemption from institutional review boards or approval for participation. All ethical approvals can be found in the [appendix (p 130)](#sec1){ref-type="sec"}.
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[^1]: Contributed equally

[^2]: Percentages might not sum to 100% because of rounding. An example of one dataset is included. AMX=amoxicillin. AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. HCQ=hydroxychloroquine. SSZ=sulfasalazine.

[^3]: AmbEMR=IQVIA Ambulatory EMR. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease Analyzer Germany. EMR=electronic medical record. HCQ=hydroxychloroquine. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM Medicare Supplemental Database. NA=non-applicable (not reported because of failed diagnostics or on-treatment follow-up unavailable). OptumEHR=Optum de-identified Electronic Health Record. SSZ=sulfasalazine. VA=US Department of Veterans Affairs.

[^4]: AmbEMR=IQVIA Ambulatory EMR. AMX=amoxicillin. AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease Analyzer Germany. EMR=electronic medical record. HCQ=hydroxychloroquine. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM Medicare Supplemental Database. NA=non-applicable (not reported because of failed diagnostics or on-treatment follow-up unavailable). OptumEHR=Optum de-identified Electronic Health Record. VA=US Department of Veterans Affairs.

[^5]: CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. HCQ=hydroxychloroquine. JMDC=Japanese Medical Data Center. MDCD=IBM Multi-state Medicaid. MDCR=IBM Medicare Supplemental Database. NA=non-applicable (not reported because of failed diagnostics or on-treatment follow-up unavailable). VA=US Department of Veterans Affairs.

[^6]: Adjusted for event-dependent observation.
